ing the first recommendation in favour of the innovation, and then subsequent entrants' prices are reduced through procurement competition as well as their lower likely required R&D investments. CONCLUSIONS: The study finds that HTA decisions on medical devices can have a material impact on the market dynamics (and so prices) following a recommendation, because of the manner in which medical devices are procured. The findings of HTA will therefore vary depending on the point in time when it is undertaken, as relative prices change substantially over time. Re-reviewing cost-effectiveness, without any new clinical evidence, relative to a technology that has had a 'disinvestment recommendation' would therefore appear perverse, as it sets up a feedback loop that causes a perpetual downward spiral in prices. The study raises a number of policy issues for consideration. These include the interplay between different drivers of value in HTA and procurement, and the implicit 'genericisation' of evidence through the procurement process.
Patel D Double Helix Consulting Group, LONDON, UK
OBJECTIVES: The current global economic climate is putting increasing pressure on governments and payers to cut health care cost but continue to fund and grant reimbursement to innovative Medicines, Devices & Biotechnologies that demonstrate benefit to patient's quality of life. One funding model that is attracting interest is patient co-payment (co-pay). Patient co-pay models are being used globally to allow patient access to medicines and medical technologies. However in United Kingdom and Europe these types of funding models are still being evaluated and assessed. A survey was designed to uncover the attitudes of physicians and patients towards co-pay models as potential funding mechanism for gaining access to new and innovative technologies. METHODS: The United Kingdom was selected to carry out research to gauge the opinions of physicians and patients towards co-pay. A total of 150 specialist physicians involved in making budget decisions were surveyed via an internet based questionnaire and in a second survey 558 patients were interviewed face to face to evaluate their attitudes towards co-pay for new and novel technologies. The results from these two surveys were statistically analysed to reveal the attitudes of these two key groups toward patient co-pay and draw some initial conclusions. RESULTS: The analysis and results from the patient survey showed that 83% of patients would consider co-pay as way of gaining access to new technologies that were not fully reimbursed by the UK public healthcare system. The physician's survey showed that 72% of the 150 of specialist supported the co-pay concept in principle. CONCLUSIONS: This UK research concluded that both physicians and patients would consider co-pay as a funding option to gain access to new technologies. Additional stakeholder research is anticipated to answer the implications surrounding equity and coverage and provide multiple stakeholders with insights into novel funding mechanisms for new technologies.
PMD51 NATIONAL TRENDS IN ADVANCED DIAGNOSTIC IMAGING USE IN OUTPATIENT SETTINGS: AN ANALYSIS OF THE MEDICAL EXPENDITURE PANEL SURVEY, 2000-2009
Lang K 1 , Huang H 1 , Lee DW 2 , Federico V 1 , Menzin J 1 1 Boston Health Economics, Inc., Waltham, MA, USA, 2 GE Healthcare, Wauwatosa, WI, USA OBJECTIVES: Concerns have been raised regarding growth in advanced diagnostic imaging use. This study evaluated national outpatient MRI/CT utilization rates during 2000-2009 and factors associated with imaging utilization. METHODS: This retrospective database analysis used data on all respondents in the nationally representative U.S. Medical Expenditure Panel Survey (MEPS) during 2000-2009. Visits involving advanced diagnostic imaging were identified based on self-reported use of MRI or CT tests at emergency rooms, office-based medical providers, and outpatient departments. The imaging utilization rate was defined as the number of outpatient visits with MRI/CT per 1,000 person-years. Results were weighted to create nationally representative estimates at the person-year level for each year and the pooled 10-year period. A multivariate logistic regression was estimated to identify predictors of imaging use. RESULTS: A total of 319,246 person-years were included in the analysis. MRI/CT utilization rates increased from 64.3 to 109.1 per 1,000 person years from 2000 to 2009, with older persons, females and Medicare enrollees having higher rates of use. Growth in imaging slowed in recent years; the average annual decline in the imaging growth rate was larger than that for all outpatient services (4.7% vs. 0.9%). The percentage of respondents with MRI/CT use (6.7% during 2000-2009) also increased at a slower rate in later years and declined during [2007] [2008] [2009] . The average number of MRI/CT visits among imaging users was steady at about 1.5 visits during 2000-2009. Age, female gender, white race, HMO participation, and all payer types (vs. uninsured) were significant predictors of imaging use. Compared to 2005, years 2000-2003 were associated with a significantly lower likelihood of imaging use , while years 2004-2009 were not significantly associated, suggesting a slow-down in later years. CONCLUSIONS: Growth in advanced imaging utilization appears to have slowed in recent years, a finding of potential interest to policy-makers and payers.
PMD52 INPATIENT REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICE AND DIAGNOSTICS IN DEVELOPED MARKETS
Lockwood C 1 , Marinoni G 1 , Gallo P 2 , Kowal S 2 1 IHS, London, UK, 2 IHS, Washington, DC, USA OBJECTIVES: The objective of this research was to examine how regulatory requirements in the inpatient setting impact the uptake and subsequent market presence of MDDs (medical devices and diagnostics). METHODS: Primary research was conducted through 48 in-depth interviews ranging from 30 to 60 minutes in length. Subjects selected represent key stakeholders from industry, insurance, government, and health services across 9 major markets (EU 5, United States, Japan, Canada, and Australia). Interview questionnaires were designed to understand the national opportunities, market access barriers, and cross-country market dynamics. This was complemented by secondary desk research that included literature reviews, government and other relevant agency websites, and IHS proprietary Healthcare and Pharmaceutical services. RESULTS: The study found that the uptake of innovative devices is affected by the reimbursement environment in hospitals as these serve as the largest consumers of MDDs. While hospitals operate under either global budgets or activity-based funding (DRG system), both funding mechanisms possess limitations to the uptake of new technologies across markets. Under global budgets, MDDs compete against other technologies and procedures for budget allocation whereas DRG systems use a flat reimbursement rate that acts as a financial disincentive to use more expensive technologies. Interviewees also highlighted additional levers that can affect MDD update, including infrequent coding system revisions, infrequent tariff updates for payments, and the existence of add-on funding mechanisms, which differ across markets. CONCLUSIONS: Across the markets considered, the inpatient reimbursement framework tends to make for fragmented and subpar uptake of innovative MDDs. Indeed, the hospital funding systems and notably infrequent revision of DRG codes, tariff updates and complex top-up payment systems, when they exist, hamper new technology uptake in an industry where incremental innovation is rapid.
PMD53 A REVIEW OF HEALTH TECHNOLOGY ASSESSMENTS (HTAS) FOR CERVICAL CANCER SCREENING TECHNOLOGIES
Lahue BJ, Baginska EA BD, Franklin Lakes, NJ, USA OBJECTIVES: To conduct a review of cervical cancer screening HTAs to understand how new technologies are evaluated. METHODS: The INAHTA website, CRD (University of York) and Avalere CER Intelligence databases, Google, and country agency websites were searched for "cervical cancer screening" and "HTA" published 2000 -2011. Reports unrelated to a screening intervention or not fully available in English were excluded. Topics, technologies, clinical results, primary or literature-based economic analysis, and incremental cost-effectiveness ratios (IC-ERs) were abstracted and analyzed. RESULTS: Twenty-five cervical cancer HTA reports were identified and 17 HTAs from 9 countries met inclusion criteria. Five technology types were evaluated: 2 cytology tests (conventional cytology (CC), liquid-based cytology (LBC)), 2 Human papillomavirus (HPV) molecular tests, and 1 computer-guided screening system. All 17 HTAs evaluated test sensitivity and specificity as the measures of clinical effectiveness. An ICER result was included in 11 HTAs with 73% (8/11) of recommendations derived from primary economic analysis. All eight HTAs reporting primary economic analysis incorporated sensitivity analyses to test various screening intervals. Six reports addressed cost-effectiveness of LBC compared to CC. Of these, 66% (4/6) concluded that LBC can be a cost-effective strategy compared to CC at specified intervals. HPV versus cytology as a primary screening test was an increasingly common topic; comparing 2000-2005 to 2006-2011, this topic's inclusion increased 63% (from 43% (3/7) -70% (7/10)). One of three HTAs reporting an ICER for HPV primary screening concluded it is a cost-effective strategy within the context of the screening program. CONCLUSIONS: Over the last 12 years, seventeen HTAs on cervical cancer screening evaluated the role of cytology and molecular testing as a primary screening intervention. Incremental cost-effectiveness (9/17), test sensitivity and specificity (17/17) and the ability to extend screening intervals (8/17) were the most common measures used in HTA to evaluate new screening technologies.
PMD54 URINE DRUG MONITORING IN THE CLINIC -WHO ARE WE TESTING, WHAT ARE WE TESTING FOR, AND HOW OFTEN ARE WE TESTING?
Clancy ZA, Couto J, O'Connell K, Moore N, Romney M Jefferson School of Population Health, Philadelphia, PA, USA OBJECTIVES: The purpose of this study is to better quantify how urine drug monitoring (UDM) is used in clinical practice. While several published studies have reported utilization of UDM in clinical practice, little is known about how often patients are monitored, which patients are monitored, which substances are important to detect, and under what circumstances clinicians modify the frequency of monitoring. METHODS: An online survey was developed based on qualitative phone interviews with eight clinicians who use UDM as a routine component of clinical practice. One thousand fourteen randomly selected clinicians known to order urine toxicology screenings were invited by mail to respond to the online survey assessing their clinical needs and preferences with regards to UDM. Ninetythree responses were received before the online survey was closed. RESULTS: Of the 93 respondents, 43% (nϭ40) self-identified as pain management specialists and another 42% (nϭ39) as family/internal medicine practitioners. Seventy-six percent of respondents (nϭ72) require all new patients to have UDM performed when they enter their clinic. The majority administer UDM to chronic opioid therapy patients four times a year. Overall, the respondents showed broad support to test patients consistently for the most common illicit drugs, the majority of opioids, and a handful of prescription medications associated with abuse. Ninety-one percent of respondents stated that all of their patients are tested for the same substances, regardless of abuse history. The most common reasons cited by clinicians for a change in the frequency of monitoring are patient history of substance abuse and aberrant behaviors. CONCLUSIONS: Despite a lack of agreement between guide-A71 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 -A 2 5 6
